IMCAS World Congress 2025
Program

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): Acorn Biolabs

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Acorn Biolabs

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Awarded and Pending
and status : Patents

This work is presented thanks to the support of: Acorn Biolabs

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Please specify entities (individual, company, society): Nova Skin

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Patents filed and licensed.
and status : 2014

This work is presented thanks to the support of: Investors

Objectives: DelNova Inc. is developing ReViVox®, a first-in-class drug product to reverse undesirable conditions from neuromodulator procedures, including muscle paralysis/weakness manifesting as eyelid or brow ptosis, unnatural facial expression, and facial-feature misalignment. In doing so, ReViVox® will strengthen providers' and patients' confidence in neuromodulators.

Introduction: Despite clinical efficacy of neurotoxins to reduce wrinkle severity, several adverse effects, such as eyelid and brow ptosis can occur. While hyaluronic acid dermal fillers have hyaluronidase, toxin has been left without an ‘eraser’ and there are currently limited methods to successfully combat these adverse effects.

Materials / method: We report the first Phase 1 study in human subjects of local administration of an anticholinesterase for reversing undesirable muscle weakness which may arise following a neurotoxin treatment.
In this proof-of-concept study, we investigated short-term effects of active ingredient (study drug) in ReViVox®, an anticholinesterase indicated for reversal of neuromuscular blockade in anesthesia.

An anonymous survey was sent to aesthetic practitioners in the US (dermatologists, plastic surgeons, nurse practitioners) to gauge the level of support for a reversal product such as ReViVox®.

Results: Our results demonstrate the study drug/active ingredient in ReViVox®, can be a potential candidate as a rescue agent to address the undesirable, localized outcomes of neurotoxin treatment.

Similar results were reported in DelNova's preclinical studies.

Survey responses were overwhelmingly in support of our product candidate, as a benefit to the aesthetic industry.

Conclusion: The absence of a 'reverser' or 'touch-up' product to address possible undesirable outcomes following neuromodulator procedures is an unmet need in aesthetics. Our proof of concept studies, both preclinical and clinical; lay the foundation for formulation optimization. Our development of ReViVox® is practical, and based on a small molecule active drug substance which has been used clinically for treating other medical conditions of muscle weakness.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): DelNova, Inc.

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): DelNova, Inc.

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Patent Granted in US and EU, pending in China, Japan, Brazil
and status : Treating of Side-Effects Resulting from Chemodenervation International PCT/US17/32636 Filed May 15 2017 and ReViVox® Trademark

This work is presented thanks to the support of: DelNova, Inc. and its private investors

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
Yes
Please specify date...: Pending
and status : January 2024

This work is presented thanks to the support of: Investors

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): CDTI

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: AI LABS GROUP SL

Objectives: 1. Define hybrosomes
2. Demonstrate the efficacy of hybrosomes
3. Present a new line of skin care and wound healing products that are more powerful than Retinol and have demonstrated reversal of cell aging

Introduction: Exosomes based therapies for skin aging are rapidly flooding the market. Their effectiveness has largely been anecdotal or published in small series comparing their use with and without a variety of microneedling devices. Herein, we present a more powerful hybrid exosome called hybrosome that is significantly more effective and has been more extensively studied by independant research facilities to validate performance in nearly 400 patients.

Materials / method: Bioengineered youthful bovine (Hybrosome) and plant exosomes (Plantosome) have been developed through a patent pending proprietary technique of membrane fusion with a liposomal agent. The bovine product has been extensively studied by independant dermatology research companies in nearly 400 patients. Blinded and randomized prospective data as well as split face data has been analyzed

Results: Hybrosomes are much more powerful than exosomes alone. Plantosomes approach the efficacy of bovine cord blood exosomes combined with liposomes. Release of the product into the marketplace has demonstrated widespread acceptance with extremely high reorder rates.

Conclusion: Hybrosomes and plantosomes are poised to become the new gold standard in regenerative medicine.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): co-founder, board member, shareholder, Mage Biotechnologies

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Mage Biotechnology

Disclosures

Did you receive any funding to support your research for this TOPIC?
No
Please specify entities (individual, company, society): Novaestiq

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Novaestiq

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No
Please specify date...: granted

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SYLKE Inc.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability